Free Trial
NASDAQ:PGNY

Progyny Q3 2025 Earnings Report

Progyny logo
$20.23 -0.20 (-0.98%)
Closing price 04:00 PM Eastern
Extended Trading
$20.01 -0.22 (-1.09%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Progyny EPS Results

Actual EPS
N/A
Consensus EPS
$0.37
Beat/Miss
N/A
One Year Ago EPS
N/A

Progyny Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Progyny Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Tuesday, November 11, 2025
Conference Call Time
4:45PM ET

Conference Call Resources

Progyny Earnings Headlines

Progyny CEO Named World Economic Forum Champion for Women’s Health
A Worldwide Gold Lockdown Is Now Underway
Central banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman Sachs VP Dr. David Eifrig says this move goes far beyond a simple bull market. In a new free presentation, he reveals why the world’s financial elite are locking down gold, what it could mean for your savings, and the three steps he recommends taking immediately.tc pixel
3 Reasons to Avoid PGNY and 1 Stock to Buy Instead
See More Progyny Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Progyny? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Progyny and other key companies, straight to your email.

About Progyny

Progyny (NASDAQ:PGNY) is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package. Through an in-house network of fertility specialists and clinics, Progyny provides members with access to pre-negotiated pricing, personalized treatment pathways and dedicated care advocates. Complementing these services is a suite of digital resources, including appointment scheduling tools, educational content and real-time treatment tracking, designed to simplify care coordination and reduce administrative burdens.

Founded in 2016, Progyny filed for its initial public offering in October 2019 and began trading on the NASDAQ under the ticker PGNY. The company was established by Michael J. Schulman, who serves as chief executive officer and has guided its growth from a startup to a publicly traded business. Under his leadership, Progyny has expanded its team of clinical advisors and invested in technology to enhance patient engagement and clinical decision support.

Progyny’s services are currently available throughout the United States, with corporate clients spanning technology, finance, manufacturing and other sectors. Headquartered in New York City, the company maintains additional offices in major U.S. markets and collaborates with employers nationwide to provide scalable, outcomes-driven fertility solutions. By combining clinical best practices with data-driven insights, Progyny seeks to set new standards in reproductive healthcare benefits.

View Progyny Profile

More Earnings Resources from MarketBeat